Iproteos, a spin-off of the University of Barcelona, merges into Accure Therapeutics
Accure Therapeutics has started its activity in the field of the Central Nervous System (CNS) by announcing a first round of funding of EUR 7.6 million. The company will develop a portfolio of candidate drugs for the treatment of CNS diseases, which are among the leading causes of disability and death worldwide, and whose prevalence is expected to increase due to demographic ageing.
The company will start working on three programmes for new drugs focused on therapeutic targets provided by Iproteos —a spin-off of the University of Barcelona (UB) and the Institute for Research on Biomedicine (IRB Barcelona)— and Bionure —a spin-off of the IDIBAPS (August Pi i Sunyer Institute for Biomedical Research) and the Spanish National Research Council (CSIC). Both Iproteos and Bionure have merged into Accure Therapeutics.
“We are proud to announce the launch of Accure Therapeutics,” said Laurent Nguyen, founder and CEO of Accure Therapeutics. “The high quality assets of our product portfolio have the potential to change the lives of patients suffering from disabling CNS diseases. Life is a gift, so we must make every effort to respect it,” he concluded.